| Symbol | PVLA |
|---|---|
| Name | PALVELLA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 353 W. LANCASTER AVE,SUITE 200, WAYNE, Pennsylvania, 19087, United States |
| Telephone | +1 484 - 253-1461 |
| Fax | — |
| — | |
| Website | https://www.palvellatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001583648 |
| Description | Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. Additional info from NASDAQ: |
Goin Kathleen 🟡 adjusted position in 4.3K shares (2 derivative) of PALVELLA THERAPEUTICS, INC. (PVLA) at $156.77 Transaction Date: Aug 19, 2026 | Filing ID: 099222
Read more📋 Goin Kathleen (Officer) plans to sell 4K shares of PALVELLA THERAPEUTICS, INC. (at $150.42 each, total $647K) Filed: Aug 19, 2026 | ID: 000044
Read morePalvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Read morePalvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read morePalvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Read morePalvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
Read moreGoin Kathleen 🟡 adjusted position in 4.3K shares (2 derivative) of PALVELLA THERAPEUTICS, INC. (PVLA) at $150.25 Transaction Date: Jul 15, 2026 | Filing ID: 084620
Read more📋 Goin Kathleen (Officer) plans to sell 4K shares of PALVELLA THERAPEUTICS, INC. (at $149.68 each, total $644K) Filed: Jul 15, 2026 | ID: 000039
Read moreDirector Pauls Matthew 🟢 acquired 6.0K shares (1 derivative) of PALVELLA THERAPEUTICS, INC. (PVLA) at $154.84 Transaction Date: Jun 29, 2026 | Filing ID: 079865
Read moreNew Form 3 - PALVELLA THERAPEUTICS, INC. <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 0001104659-26-079863 <b>Size:</b> 8 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07552077 | A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-… | Phase2 | Angiokeratomas | Recruiting | 2026-04-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06653842 | A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-… | Phase2 | Cutaneous Venous Malformations | Active_Not_Recruiting | 2024-12-20 | 2026-03-01 | ClinicalTrials.gov |
| NCT06239480 | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Tr… | Phase3 | Microcystic Lymphatic Malformation | Active_Not_Recruiting | 2024-07-31 | 2026-07-01 | ClinicalTrials.gov |
| NCT05643872 | A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anh… | Phase3 | Pachyonychia Congenita | Recruiting | 2022-11-15 | 2023-11-01 | ClinicalTrials.gov |
| NCT05050149 | Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the T… | Phase2 | Microcystic Lymphatic Malformation | Completed | 2022-01-13 | 2022-12-15 | ClinicalTrials.gov |
| NCT05180708 | A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evalu… | Phase3 | Pachyonychia Congenita | Completed | 2021-11-29 | 2023-06-30 | ClinicalTrials.gov |
| NCT04893486 | CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topic… | Phase2 | BCCs in Gorlin Syndrome Patients | Completed | 2021-05-06 | 2023-03-13 | ClinicalTrials.gov |
| NCT04520750 | VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of … | Phase3 | Pachyonychia Congenita | Completed | 2020-09-01 | 2022-12-15 | ClinicalTrials.gov |
| NCT03920228 | Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of A… | Phase2 | Pachyonychia Congenita | Completed | 2019-04-01 | 2020-10-19 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PTX-022 | Other | Phase PHASE3 | Pachyonychia Congenita | RECRUITING | NCT05643872 |
| Vehicle | Other | Phase PHASE3 | Pachyonychia Congenita | COMPLETED | NCT05180708 |
| QTORIN 3.9% rapamycin anhydrous gel | Other | Phase PHASE3 | Pachyonychia Congenita | COMPLETED | NCT05180708 |
| Vehicle comparator | Other | Phase PHASE2 | BCCs in Gorlin Syndrome Patients | COMPLETED | NCT04893486 |
| PTX-022 | Other | Phase PHASE2 | BCCs in Gorlin Syndrome Patients | COMPLETED | NCT04893486 |
| PTX-022 | Other | Phase PHASE3 | Pachyonychia Congenita | COMPLETED | NCT04520750 |
| Placebo | Other | Phase PHASE2 | Pachyonychia Congenita | COMPLETED | NCT03920228 |
| PTX-022 | Other | Phase PHASE2 | Pachyonychia Congenita | COMPLETED | NCT03920228 |
| PTX-022 | Other | Phase PHASE2 | Microcystic Lymphatic Malformation | COMPLETED | NCT05050149 |
| QTORIN 3.9% rapamycin anhydrous gel | Other | Phase PHASE2 | Cutaneous Venous Malformations | ACTIVE_NOT_RECRUITING | NCT06653842 |
| QTORIN 3.9% Rapamycin Anhydrous Gel | Other | Phase PHASE3 | Microcystic Lymphatic Malformation | ACTIVE_NOT_RECRUITING | NCT06239480 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| PTX-022 | Other | Phase PHASE2 | Angiokeratomas | RECRUITING | NCT07552077 |
| QTORIN 3.9% Rapamycin Anhydrous Gel | DRUG | Phase PHASE3 | Microcystic Lymphatic Malformation | ACTIVE_NOT_RECRUITING | NCT06239480 |
| Vehicle | DRUG | Phase PHASE3 | Pachyonychia Congenita | COMPLETED | NCT05180708 |
| QTORIN 3.9% rapamycin anhydrous gel | DRUG | Phase PHASE2 | Cutaneous Venous Malformations | ACTIVE_NOT_RECRUITING | NCT06653842 |
| Vehicle comparator | DRUG | Phase PHASE2 | BCCs in Gorlin Syndrome Patients | COMPLETED | NCT04893486 |
| Placebo | DRUG | Phase PHASE2 | Pachyonychia Congenita | COMPLETED | NCT03920228 |
| PTX-022 | DRUG | Phase PHASE3 | Pachyonychia Congenita | RECRUITING | NCT05643872 |